Skip to main content

Table 2 Basic characteristics of included studies for plasma ptau181 analysis

From: Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis

Study Subjects (n) Male (%) Age, years (mean ± SD) P-tau-181 (pg/ml) Research question Method
Suárez-Calvet et al. (2020) [84] CN (250) 38 60.6 ± 4.44 8.83 ± 3.21 1 Simoa - Karikari method
Moscoso et al. (2021) [85] CN (374) 47.1 74.8 ± 6.6 13.3 ± 10.7 1 Simoa - Karikari method
O’Connor et al. (2020) [86] CN (27) 41 38.1 ± 10.7 9.7 ± 9.3 1, 2 and 3 Simoa - Karikari method
AD (19) 63 50.7 ± 10.0 23.7 ± 10.5
Rodriguez et al. (2020) [87] CN (28) 35.7 82.2 ± 6.5 19.3 ± 9.9 1, 2 and 3 Simoa - Karikari method
AD (77) 46.1 81.7 ± 7.6 28.4 ± 9.6
Karikari et al. (2020) - TRIAD cohort [88] CN-young (27) 37 22.7 ± 1.9 7.9 ± 2.6 1, 2 and 3 Simoa - Karikari method
CN-old (113) 36 69.2 ± 9.7 10 ± 3.3
AD (33) 55 64.6 ± 9.2 24.9 ± 7.8
Karikari et al. (2020) -BioFINDER-2 cohort [88] CN-old (337) 46 63.1 ± 5.0 9.4 ± 6.0 1, 2 and 3 Simoa - Karikari method
AD (126) 47 74.0 ± 6.9 19.2 ± 9.4
Karikari et al. (2020) [45] CN (268) 51.1 73.5 ± 6.5 14.2 ± 9.0 1, 2 and 3 Simoa - Karikari method
AD (137) 52.2 73.4 ± 8.2 25.8 ± 8.6
Mielke et al. (2018) [60] CN (172) 69.2 71.9 ± 9.5 6.4 ± 6.4 1, 2 and 3 MSD
AD (40) 23 67.7 ± 9.2 11.6 ± 4.1
Thijssen et al. (2020) [89] CN (69) 53.6 60.8 ± 22 2.4 ± 3 1, 2 and 3 MSD
AD (56) 41.1 65 ± 9 8.4 ± 4
Janelidze et al. (2020) - Cohort1 [90] CN (26) 38.5 74 ± 5.2 1.3 ± 1.1 1, 2 and 3 MSD
AD (38) 44.7 73 ± 8.1 4.4 ± 2.3
Janelidze et al. (2020) - Cohort2 [90] CN (126) 61.9 71 ± 5.2 1.2 ± 0.59 1, 2 and 3 MSD
AD (81) 43.2 73 ± 5.2 2.8 ± 2.07
Janelidze et al. (2020) – Cohort3 [90] CN (47) 59.6 83 ± 9.6 1.8 ± 1.04 1, 2 and 3 MSD
AD (16) 75.0 83 ± 7.4 4 ± 2.07